Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Tue, 23.04.2024
Evotec SE
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the appointment of Dr Christian Wojczewski as Chief Executive Officer of the Company, effective 01 July 2024. Dr Wojczewski holds a degree in chemistry and has over 20 years of experience in various man [ … ]
Thu, 18.04.2024
Evotec SE
COLLABORATION LEVERAGES VARIANT BIO’S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC’S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS
COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMM [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with her a wealth of experience and experti [ … ]
Wed, 06.03.2024
Evotec SE
CLARIS’S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC’S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES
AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS’S PORTFOLIO COMPANY IAMA
Hamburg, Germany, and Turin, Italy, 06 March 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, [ … ]
Wed, 07.02.2024
Evotec SE
JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV
AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV
Hamburg, Germany, 07 February 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; [ … ]
Mon, 22.01.2024
Evotec SE
Hamburg, Germany, 22 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari [ … ]
Wed, 10.01.2024
Evotec SE
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”)
THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR [ … ]
Mon, 08.01.2024
Evotec SE
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH
Hamburg, Germany, 08 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer [ … ]
Thu, 04.01.2024
Evotec SE
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM
A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC
AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC
Hamburg, Germany, and Paris, France, 04 Janu [ … ]